Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
Shu YJ, He JF, Pei RJ, He P, Huang ZH, Chen SM, Ou ZQ, Deng JL, Zeng PY, Zhou J, Min YQ, Deng F, Peng H, Zhang Z, Wang B, Xu ZH, Guan WX, Hu ZY, Zhang JK. Shu YJ, et al. Among authors: pei rj. Chin Med J (Engl). 2021 Jul 22;134(16):1967-1976. doi: 10.1097/CM9.0000000000001702. Chin Med J (Engl). 2021. PMID: 34310400 Free PMC article. Clinical Trial.
Ozone Water Is an Effective Disinfectant for SARS-CoV-2.
Hu X, Chen Z, Su Z, Deng F, Chen X, Yang Q, Li P, Chen Q, Ma J, Guan W, Pei R, Wang Y. Hu X, et al. Virol Sin. 2021 Oct;36(5):1066-1068. doi: 10.1007/s12250-021-00379-7. Epub 2021 Mar 31. Virol Sin. 2021. PMID: 33788169 Free PMC article. No abstract available.
Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.
Zhang J, Hu Z, He J, Liao Y, Li Y, Pei R, Fang X, Zeng P, Fan R, Ou Z, Deng J, Zhou J, Guan W, Min Y, Deng F, Peng H, Zhang Z, Feng C, Xin B. Zhang J, et al. Emerg Microbes Infect. 2021 Dec;10(1):1589-1597. doi: 10.1080/22221751.2021.1951126. Emerg Microbes Infect. 2021. PMID: 34197281 Free PMC article. Clinical Trial.
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.
Wang XY, Mahmood SF, Jin F, Cheah WK, Ahmad M, Sohail MA, Ahmad W, Suppan VK, Sayeed MA, Luxmi S, Teo AH, Lee LY, Qi YY, Pei RJ, Deng W, Xu ZH, Yang JM, Zhang Y, Guan WX, Yu X. Wang XY, et al. Among authors: pei rj. Emerg Microbes Infect. 2022 Dec;11(1):1910-1919. doi: 10.1080/22221751.2022.2088406. Emerg Microbes Infect. 2022. PMID: 35686572 Free PMC article. Clinical Trial.
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
Chen GL, Yu XY, Luo LP, Zhang F, Dai XH, Li N, Shen ZW, Wu KQ, Lou DF, Peng CG, Jin TH, Huang YM, Shao X, Liu Q, Jiang Q, Guo T, Cao F, Zhu JR, Wu XH, Pei RJ, Deng F, Jiang GP, Li YH, Gao HN, He JX, Zhong-Chen, Peng YC, Li LJ. Chen GL, et al. Among authors: pei rj. Vaccine. 2023 Nov 22;41(48):7297-7306. doi: 10.1016/j.vaccine.2023.10.065. Epub 2023 Nov 3. Vaccine. 2023. PMID: 37925316 Free article. Clinical Trial.
Vaccinia virus tiantan strain is inefficient in eliciting cross-reactive immunity against the emerging monkeypox virus strain.
Tian L, Zhang Y, Liu Q, Ruan L, Ren F, Han Y, Zhang Y, Yang L, Li S, Sun H, Zhang Y, Zhou Y, Pei R, Deng F, Huang C, Chen X, Wang Y. Tian L, et al. Emerg Microbes Infect. 2024 Dec;13(1):2306967. doi: 10.1080/22221751.2024.2306967. Epub 2024 Jan 30. Emerg Microbes Infect. 2024. PMID: 38240366 Free PMC article. No abstract available.
113 results